profit from every CHF 100 of sales.
CHF 0CHF 100
Kuros Biosciences
CHF 19.47-1.17% today
-30.1% in 1 year
1-year low CHF 16.461-year high CHF 29.40
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kuros Biosciences sold, what it kept, and what it did with the cash.
Sales went from $18.0 million in 2022 to $146 million in 2025, with $2.55 million of profit last year.
SalesProfit
Kuros Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Kuros Biosciences | No profit yet | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Kuros Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 18 | 34 | 85 | 146 | |
| 11 | 24 | 70 | 129 | |
| -13 | -10 | -6 | 9 | |
| -13 | -7 | -1 | 9 | |
| -15 | -10 | -5 | 3 | |
| -0.43 | -0.38 | -0.13 | – | |
| 59.9% | 71.3% | 82.1% | 88.6% | |
| -74.8% | -28.7% | -6.6% | 6.1% | |
| -81.1% | -30.3% | -5.7% | 1.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 83 | 71 | 93 | 134 |
| Cash | 24 | 14 | 20 | 19 |
| Total debt | 2 | 2 | 2 | 1 |
| Total liabilities | 14 | 15 | 28 | 49 |
| 69 | 57 | 64 | 84 | |
| 34 | 37 | 37 | – | |
| -19.0% | -13.9% | -4.6% | 5.3% | |
| -21.2% | -17.9% | -7.5% | 3.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -9 | 4 | -0 | |
| 0 | 0 | 1 | 2 | |
| -8 | -9 | 2 | -3 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 6 | 4 |
Valuation
- –
- –
- –
- 10.9×
- –
- –
- –
- –
- –
- –
Profitability
- 88.6%
- 6.1%
- 1.7%
- –
- 5.3%
- -8.0%
- –
- –
- –
- –
Growth
- +101.0%
- –
- –
- –
- +6.9%
Financial health
- -2.0×
- 0.02
- –
- 14.7×
- 1.96
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 49%of 952
Bottom 40%of 884
Top 5%of 887
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
36No pass
Philip Fisher
42No pass
Peter Lynch
65Pass
Joel Greenblatt
3No pass
Charlie Munger
33No pass
Terry Smith
27No pass
Questions about Kuros Biosciences
Is Kuros Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kuros Biosciences AI analysis
What does Kuros Biosciences do?
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. It is in Medical Devices, based in Schlieren, Switzerland, with 178 employees.
Is Kuros Biosciences stock halal?
Yes. Kuros Biosciences passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Kuros Biosciences stock done over the past year?
Down 30.1% over the past twelve months, to CHF 19.47. It traded between CHF 16.46 and CHF 29.40 and is 33.8% below its high.
Who are Kuros Biosciences's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Kuros Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.